Literature DB >> 9894246

P53 in breast carcinomas: association between presence of mutation and immunohistochemical expression using a semiquantitative approach.

F C Schmitt1, R Soares, L Cirnes, R Seruca.   

Abstract

The aim of this study was to evaluate the concordance between the presence of p53 mutations in breast carcinomas expressing the protein by immunohistochemistry. A series of 60 breast carcinomas was evaluated by immunohistochemistry using monoclonal antibodies against p53 protein (DO 7 and PAb 1801). Twenty cases classified as being positive for p53 according to the current approach (if 5% or more of neoplastic cells contained reaction product in the nucleus) were used for molecular studies. These cases were re-assessed semi-quantitatively using a scoring system based on intensity and percentage of stained cells. DNA was phenol-chloroform extracted from microdissected normal and tumour cells obtained from formalin-fixed, paraffin-embedded tissue sections. Mutations in the p53 gene were analysed by SSCP (single strand conformational polymorphism) with primers covering exons 2-3 to 11. Ten out of the 20 p53-positive cases presented mutations detected by SSCP analysis. Mutations have been found in several exons ranging from exon 4 to exon 10. We observed a positive relationship between the presence of mutations and immunohistochemical evaluation of p53 protein expression using a semiquantitative scoring system. All cases with more than 2/3 stained tumour cells and strong intensity of staining exhibited p53 mutations. At variance, no p53 mutations were found in cases with less than 1/3 stained tumour cells and moderate intensity of staining. Therefore, only the identification of positivity for p53 detected by immunohistochemistry did not always reflect the detection of p53 mutations in breast cancer, however the use of a semi-quantitative approach seems to be useful as an indicator of the presence of mutation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9894246     DOI: 10.1016/s0344-0338(98)80083-6

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  7 in total

1.  p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin.

Authors:  T Megha; F Ferrari; A Benvenuto; C Bellan; A V Lalinga; S Lazzi; S Bartolommei; G Cevenini; L Leoncini; P Tosi
Journal:  J Clin Pathol       Date:  2002-06       Impact factor: 3.411

2.  The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 status.

Authors:  Wolfgang J Köstler; Thomas Brodowicz; Gernot Hudelist; Margaretha Rudas; Reinhard Horvat; Günther G Steger; Christian F Singer; Johannes Attems; Werner Rabitsch; Negar Fakhrai; Katarzyna Elandt; Christoph Wiltschke; Michael Hejna; Christoph C Zielinski
Journal:  J Cancer Res Clin Oncol       Date:  2005-04-29       Impact factor: 4.553

3.  Most basal-like breast carcinomas demonstrate the same Rb-/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically.

Authors:  Andrea Proctor Subhawong; Ty Subhawong; Hind Nassar; Nina Kouprina; Shahnaz Begum; Russell Vang; William H Westra; Pedram Argani
Journal:  Am J Surg Pathol       Date:  2009-02       Impact factor: 6.394

Review 4.  TP53 status and response to treatment in breast cancers.

Authors:  Mariana Varna; Guilhem Bousquet; Louis-François Plassa; Philippe Bertheau; Anne Janin
Journal:  J Biomed Biotechnol       Date:  2011-05-09

5.  p53 mutations in classic and pleomorphic invasive lobular carcinoma of the breast.

Authors:  Cigdem Ercan; Paul J van Diest; Bram van der Ende; John Hinrichs; Peter Bult; Horst Buerger; Elsken van der Wall; Patrick W B Derksen
Journal:  Cell Oncol (Dordr)       Date:  2012-02-22       Impact factor: 6.730

6.  Mutations in p53, p53 protein overexpression and breast cancer survival.

Authors:  Pavel Rossner; Marilie D Gammon; Yu-Jing Zhang; Mary Beth Terry; Hanina Hibshoosh; Lorenzo Memeo; Mahesh Mansukhani; Chang-Min Long; Gail Garbowski; Meenakshi Agrawal; Tara S Kalra; Mia M Gaudet; Susan L Teitelbaum; Alfred I Neugut; Regina M Santella
Journal:  J Cell Mol Med       Date:  2008-10-16       Impact factor: 5.310

7.  Elevated mammaglobin (h-MAM) expression in breast cancer is associated with clinical and biological features defining a less aggressive tumour phenotype.

Authors:  M J Núñez-Villar; F Martínez-Arribas; M Pollán; A R Lucas; J Sánchez; A Tejerina; J Schneider
Journal:  Breast Cancer Res       Date:  2003-03-06       Impact factor: 6.466

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.